| Year |
Citation |
Score |
| 2021 |
Seimiya H, Nagasawa K, Shin-Ya K. Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. The Journal of Antibiotics. PMID 34285374 DOI: 10.1038/s41429-021-00454-x |
0.308 |
|
| 2020 |
Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H, Yamaguchi K. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. International Journal of Colorectal Disease. PMID 32920703 DOI: 10.1007/S00384-020-03748-Y |
0.315 |
|
| 2020 |
Seimiya H. Crossroads of telomere biology and anticancer drug discovery. Cancer Science. PMID 32579791 DOI: 10.1111/Cas.14540 |
0.449 |
|
| 2020 |
Tomizawa F, Jang MK, Mashima T, Seimiya H. c-KIT regulates stability of cancer stemness in CD44-positive colorectal cancer cells. Biochemical and Biophysical Research Communications. PMID 32439168 DOI: 10.1016/J.Bbrc.2020.05.024 |
0.374 |
|
| 2020 |
Nakanishi C, Seimiya H. G-quadruplex in cancer biology and drug discovery. Biochemical and Biophysical Research Communications. PMID 32312519 DOI: 10.1016/J.Bbrc.2020.03.178 |
0.359 |
|
| 2020 |
Shirai F, Mizutani A, Yashiroda Y, Tsumura T, Kano Y, Muramatsu Y, Chikada T, Yuki H, Niwa H, Sato S, Washizuka K, Koda Y, Mazaki Y, Jang MK, Yoshida H, ... ... Seimiya H, et al. Design and Discovery of an Orally Efficacious Spiroindolinone-based Tankyrase Inhibitor for the Treatment of Colon Cancer. Journal of Medicinal Chemistry. PMID 32202790 DOI: 10.1021/Acs.Jmedchem.0C00045.S002 |
0.378 |
|
| 2020 |
Kawakami R, Mashima T, Kawata N, Kumagai K, Migita T, Sano T, Mizunuma N, Yamaguchi K, Seimiya H. ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. Cancer Science. PMID 31960523 DOI: 10.1111/Cas.14316 |
0.438 |
|
| 2020 |
Jang MK, Mashima T, Seimiya H. Tankyrase inhibitors target colorectal cancer stem cells via AXIN-dependent downregulation of c-KIT tyrosine kinase. Molecular Cancer Therapeutics. PMID 31907221 DOI: 10.1158/1535-7163.Mct-19-0668 |
0.431 |
|
| 2020 |
Suenaga M, Mashima T, Kawata N, Wakatsuki T, Seimiya H, Yamaguchi K. Circulating IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer. Journal of Clinical Oncology. 38: 172-172. DOI: 10.1200/Jco.2020.38.4_Suppl.172 |
0.343 |
|
| 2019 |
Okamoto K, Seimiya H. From the wings to the center stage of chromosomes. The Journal of Biological Chemistry. 294: 17723-17724. PMID 31757801 DOI: 10.1074/Jbc.H119.011587 |
0.336 |
|
| 2019 |
Mashima T, Iwasaki R, Kawata N, Kawakami R, Kumagai K, Migita T, Sano T, Yamaguchi K, Seimiya H. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells. British Journal of Cancer. PMID 31607750 DOI: 10.1038/S41416-019-0600-9 |
0.39 |
|
| 2019 |
Shirai F, Tsumura T, Yashiroda Y, Yuki H, Niwa H, Sato S, Chikada T, Koda Y, Washizuka K, Yoshimoto N, Abe M, Onuki T, Mazaki Y, Hirama C, Fukami T, ... ... Seimiya H, et al. Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors. Journal of Medicinal Chemistry. PMID 30883102 DOI: 10.2210/Pdb5Zqr/Pdb |
0.387 |
|
| 2019 |
Okamoto K, Seimiya H. Revisiting Telomere Shortening in Cancer. Cells. 8. PMID 30709063 DOI: 10.3390/Cells8020107 |
0.446 |
|
| 2018 |
Okamoto K, Ohishi T, Kuroiwa M, Iemura SI, Natsume T, Seimiya H. MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs. Oncotarget. 9: 35844-35855. PMID 30533199 DOI: 10.18632/Oncotarget.26312 |
0.388 |
|
| 2018 |
Fujiwara C, Muramatsu Y, Nishii M, Tokunaka K, Tahara H, Ueno M, Yamori T, Sugimoto Y, Seimiya H. Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. Scientific Reports. 8: 14827. PMID 30287851 DOI: 10.1038/S41598-018-33139-X |
0.445 |
|
| 2018 |
Mizutani A, Yashiroda Y, Muramatsu Y, Yoshida H, Chikada T, Tsumura T, Okue M, Shirai F, Fukami T, Yoshida M, Seimiya H. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Science. PMID 30238564 DOI: 10.1111/Cas.13805 |
0.418 |
|
| 2018 |
Suenaga M, Mashima T, Kawata N, Dan S, Wakatsuki T, Shinozaki E, Ichimura T, Ogura M, Takahari D, Osumi H, Ota Y, Chin K, Seimiya H, Yamaguchi K, Yamaguchi T. Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation. Journal of Clinical Oncology. 36: 669-669. DOI: 10.1200/Jco.2018.36.4_Suppl.669 |
0.366 |
|
| 2018 |
Okabe S, Nakamura T, Hasegawa D, Kojima R, Okamoto K, Nakano I, Shin-ya K, Nagasawa K, Seimiya H. Abstract 4839: Targeting glioma stem cells by pharmacologic stabilization of G-quadruplexes Cancer Research. 78: 4839-4839. DOI: 10.1158/1538-7445.Am2018-4839 |
0.429 |
|
| 2017 |
Nakamura T, Okabe S, Yoshida H, Iida K, Ma Y, Sasaki S, Yamori T, Shin-Ya K, Nakano I, Nagasawa K, Seimiya H. Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. Scientific Reports. 7: 3605. PMID 28620243 DOI: 10.1038/S41598-017-03785-8 |
0.413 |
|
| 2017 |
Mashima T, Taneda Y, Jang MK, Mizutani A, Muramatsu Y, Yoshida H, Sato A, Tanaka N, Sugimoto Y, Seimiya H. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer. Oncotarget. PMID 28615517 DOI: 10.18632/Oncotarget.18146 |
0.388 |
|
| 2017 |
Migita T, Ueda A, Ohishi T, Hatano M, Seimiya H, Horiguchi SI, Koga F, Shibasaki F. Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 28240746 DOI: 10.1038/Labinvest.2017.17 |
0.387 |
|
| 2017 |
Ohishi T, Yoshida H, Katori M, Migita T, Muramatsu Y, Miyake M, Ishikawa Y, Saiura A, Iemura SI, Natsume T, Seimiya H. Tankyrase-binding protein TNKS1BP1 regulates actin cytoskeleton rearrangement and cancer cell invasion. Cancer Research. PMID 28202517 DOI: 10.1158/0008-5472.Can-16-1846 |
0.413 |
|
| 2017 |
Tanaka N, Mashima T, Mizutani A, Sato A, Aoyama A, Gong B, Yoshida H, Muramatsu Y, Nakata K, Matsuura M, Katayama R, Nagayama S, Fujita N, Sugimoto Y, Seimiya H. APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer. Molecular Cancer Therapeutics. PMID 28179481 DOI: 10.1158/1535-7163.Mct-16-0578 |
0.363 |
|
| 2017 |
Ohishi T, Yoshida H, Katori M, Migita T, Muramatsu Y, Miyake M, Ishikawa Y, Saiura A, Iemura S, Natsume T, Seimiya H. Abstract 1882: Tankyrase-binding protein TNKS1BP1 regulates cancer cell invasion Cancer Research. 77: 1882-1882. DOI: 10.1158/1538-7445.Am2017-1882 |
0.396 |
|
| 2016 |
Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, et al. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. Cancer Science. 107: 189-202. PMID 26919617 DOI: 10.1111/Cas.12857 |
0.342 |
|
| 2016 |
Hasegawa D, Okabe S, Okamoto K, Nakano I, Shin-Ya K, Seimiya H. G-quadruplex ligand-induced DNA damage response coupled with telomere dysfunction and replication stress in glioma stem cells. Biochemical and Biophysical Research Communications. PMID 26845351 DOI: 10.1016/J.Bbrc.2016.01.176 |
0.407 |
|
| 2016 |
Ouchi R, Okabe S, Migita T, Nakano I, Seimiya H. Senescence from glioma stem cell differentiation promotes tumor growth. Biochemical and Biophysical Research Communications. PMID 26775840 DOI: 10.1016/J.Bbrc.2016.01.071 |
0.344 |
|
| 2015 |
Mizutani A, Koinuma D, Seimiya H, Miyazono K. The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma. Oncogene. PMID 26522722 DOI: 10.1038/Onc.2015.412 |
0.376 |
|
| 2015 |
Seimiya H. Predicting Risk at the End of the End: Telomere G-tail as a Biomarker. Ebiomedicine. 2: 802-3. PMID 26425685 DOI: 10.1016/J.Ebiom.2015.07.006 |
0.342 |
|
| 2015 |
Mashima T, Ushijima M, Matsuura M, Tsukahara S, Kunimasa K, Furuno A, Saito S, Kitamura M, Soma-Nagae T, Seimiya H, Dan S, Yamori T, Tomida A. Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation. Cancer Science. 106: 909-20. PMID 25911996 DOI: 10.1111/Cas.12682 |
0.308 |
|
| 2015 |
Hirashima K, Seimiya H. Telomeric repeat-containing RNA/G-quadruplex-forming sequences cause genome-wide alteration of gene expression in human cancer cells in vivo. Nucleic Acids Research. 43: 2022-32. PMID 25653161 DOI: 10.1093/Nar/Gkv063 |
0.437 |
|
| 2015 |
Hirashima K, Seimiya H. Abstract 3870: Telomeric non-coding RNA causes genome-wide alteration of gene expression in cancer Cancer Research. 75: 3870-3870. DOI: 10.1158/1538-7445.Am2015-3870 |
0.45 |
|
| 2015 |
Mizutani A, Koinuma D, Seimiya H, Miyazono K. Abstract 2131: The Arkadia-ESRP2 axis suppresses tumor progression: Analyses in clear cell renal cell carcinoma Cancer Research. 75: 2131-2131. DOI: 10.1158/1538-7445.Am2015-2131 |
0.302 |
|
| 2014 |
Shimamoto A, Kagawa H, Zensho K, Sera Y, Kazuki Y, Osaki M, Oshimura M, Ishigaki Y, Hamasaki K, Kodama Y, Yuasa S, Fukuda K, Hirashima K, Seimiya H, Koyama H, et al. Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. Plos One. 9: e112900. PMID 25390333 DOI: 10.1371/Journal.Pone.0112900 |
0.372 |
|
| 2014 |
Mashima T, Soma-Nagae T, Migita T, Kinoshita R, Iwamoto A, Yuasa T, Yonese J, Ishikawa Y, Seimiya H. TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Research. 74: 4888-97. PMID 24962028 DOI: 10.1158/0008-5472.Can-13-3718 |
0.355 |
|
| 2014 |
Ohishi T, Muramatsu Y, Yoshida H, Seimiya H. TRF1 ensures the centromeric function of Aurora-B and proper chromosome segregation. Molecular and Cellular Biology. 34: 2464-78. PMID 24752893 DOI: 10.1128/Mcb.00161-14 |
0.375 |
|
| 2014 |
Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, Soga T, Taguchi R, Seimiya H. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells. International Journal of Cancer. Journal International Du Cancer. 135: 37-47. PMID 24310723 DOI: 10.1002/Ijc.28652 |
0.303 |
|
| 2014 |
Mashima T, Soma-Nagae T, Migita T, Kinoshita R, Iwamoto A, Yuasa T, Yonese J, Ishikawa Y, Seimiya H. Abstract LB-51: TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival via the regulation of endoplasmic reticulum chaperone expression Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-51 |
0.371 |
|
| 2013 |
Hirashima K, Migita T, Sato S, Muramatsu Y, Ishikawa Y, Seimiya H. Telomere length influences cancer cell differentiation in vivo. Molecular and Cellular Biology. 33: 2988-95. PMID 23716593 DOI: 10.1128/Mcb.00136-13 |
0.467 |
|
| 2013 |
Iida K, Majima S, Nakamura T, Seimiya H, Nagasawa K. Evaluation of the interaction between long telomeric DNA and macrocyclic hexaoxazole (6OTD) dimer of a G-quadruplex ligand. Molecules (Basel, Switzerland). 18: 4328-41. PMID 23584054 DOI: 10.3390/Molecules18044328 |
0.309 |
|
| 2013 |
Migita T, Okabe S, Ikeda K, Igarashi S, Sugawara S, Tomida A, Taguchi R, Soga T, Seimiya H. Inhibition of ATP citrate lyase induces an anticancer effect via reactive oxygen species: AMPK as a predictive biomarker for therapeutic impact. The American Journal of Pathology. 182: 1800-10. PMID 23506848 DOI: 10.1016/J.Ajpath.2013.01.048 |
0.366 |
|
| 2013 |
Iida K, Tsubouchi G, Nakamura T, Majima S, Seimiya H, Nagasawa K. Interaction of long telomeric DNAs with macrocyclic hexaoxazole as a G-quadruplex ligand Medchemcomm. 4: 260-264. DOI: 10.1039/C2Md20234D |
0.311 |
|
| 2012 |
Kawahara T, Hosoya T, Tsukamoto M, Okabe S, Yamamura H, Hayakawa M, Seimiya H, Takagi M, Shin-Ya K. JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells. The Journal of Antibiotics. 65: 373-5. PMID 22534652 DOI: 10.1038/Ja.2012.32 |
0.324 |
|
| 2012 |
Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, Nakano I. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1268-80. PMID 22230766 DOI: 10.1158/1078-0432.Ccr-11-1795 |
0.367 |
|
| 2011 |
Takahashi K, Imano R, Kibe T, Seimiya H, Muramatsu Y, Kawabata N, Tanaka G, Matsumoto Y, Hiromoto T, Koizumi Y, Nakazawa N, Yanagida M, Yukawa M, Tsuchiya E, Ueno M. Fission yeast Pot1 and RecQ helicase are required for efficient chromosome segregation. Molecular and Cellular Biology. 31: 495-506. PMID 21098121 DOI: 10.1128/Mcb.00613-10 |
0.332 |
|
| 2011 |
Miyazaki T, Pan Y, Hu B, Demir H, Joshi K, Okabe S, Yamori T, Viapiano M, Shin-ya K, Seimiya H, Nakano I. Abstract 3302: The effects of the g-quadruplex ligand telomestatin to human brain tumor stem cell survival and growth Cancer Research. 71: 3302-3302. DOI: 10.1158/1538-7445.Am2011-3302 |
0.397 |
|
| 2010 |
Mashima T, Okabe S, Seimiya H. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth. Molecular Pharmacology. 78: 846-54. PMID 20709811 DOI: 10.1124/Mol.110.064790 |
0.37 |
|
| 2010 |
Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D, Nakata H, Tohyama S, Hashimoto H, Kodaira M, Okada Y, Seimiya H, Fusaki N, Hasegawa M, Fukuda K. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 7: 11-4. PMID 20621043 DOI: 10.1016/J.Stem.2010.06.003 |
0.308 |
|
| 2010 |
Yashiroda Y, Okamoto R, Hatsugai K, Takemoto Y, Goshima N, Saito T, Hamamoto M, Sugimoto Y, Osada H, Seimiya H, Yoshida M. A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochemical and Biophysical Research Communications. 394: 569-73. PMID 20214890 DOI: 10.1016/J.Bbrc.2010.03.021 |
0.376 |
|
| 2010 |
Ohishi T, Hirota T, Tsuruo T, Seimiya H. TRF1 mediates mitotic abnormalities induced by Aurora-A overexpression. Cancer Research. 70: 2041-52. PMID 20160025 DOI: 10.1158/0008-5472.Can-09-2008 |
0.375 |
|
| 2010 |
Migita T, Narita T, Asaka R, Miyagi E, Nagano H, Nomura K, Matsuura M, Satoh Y, Okumura S, Nakagawa K, Seimiya H, Ishikawa Y. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. The American Journal of Pathology. 176: 1756-66. PMID 20150439 DOI: 10.2353/Ajpath.2010.090500 |
0.327 |
|
| 2010 |
Kobayashi Y, Sato K, Kibe T, Seimiya H, Nakamura A, Yukawa M, Tsuchiya E, Ueno M. Expression of mutant RPA in human cancer cells causes telomere shortening. Bioscience, Biotechnology, and Biochemistry. 74: 382-5. PMID 20139621 DOI: 10.1271/Bbb.90496 |
0.428 |
|
| 2009 |
Mashima T, Sato S, Okabe S, Miyata S, Matsuura M, Sugimoto Y, Tsuruo T, Seimiya H. Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Science. 100: 1556-62. PMID 19459852 DOI: 10.1111/J.1349-7006.2009.01203.X |
0.398 |
|
| 2009 |
Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. British Journal of Cancer. 100: 1369-72. PMID 19352381 DOI: 10.1038/Sj.Bjc.6605007 |
0.33 |
|
| 2009 |
McCabe N, Cerone MA, Ohishi T, Seimiya H, Lord CJ, Ashworth A. Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene. 28: 1465-70. PMID 19182824 DOI: 10.1038/Onc.2008.483 |
0.383 |
|
| 2009 |
Mashima T, Sato S, Sugimoto Y, Tsuruo T, Seimiya H. Promotion of glioma cell survival by acyl-CoA synthetase 5 under extracellular acidosis conditions. Oncogene. 28: 9-19. PMID 18806831 DOI: 10.1038/Onc.2008.355 |
0.382 |
|
| 2008 |
Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, Okumura S, Nakagawa K, Ishikawa Y. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Research. 68: 8547-54. PMID 18922930 DOI: 10.1158/0008-5472.Can-08-1235 |
0.402 |
|
| 2008 |
Muramatsu Y, Tahara H, Ono T, Tsuruo T, Seimiya H. Telomere elongation by a mutant tankyrase 1 without TRF1 poly(ADP-ribosyl)ation. Experimental Cell Research. 314: 1115-24. PMID 18221737 DOI: 10.1016/J.Yexcr.2007.12.005 |
0.338 |
|
| 2007 |
Ohishi T, Tsuruo T, Seimiya H. Evaluation of tankyrase inhibition in whole cells. Methods in Molecular Biology (Clifton, N.J.). 405: 133-46. PMID 18369822 DOI: 10.1007/978-1-60327-070-0_11 |
0.449 |
|
| 2007 |
Tanaka E, Fukuda H, Nakashima K, Tsuchiya N, Seimiya H, Nakagama H. HnRNP A3 binds to and protects mammalian telomeric repeats in vitro. Biochemical and Biophysical Research Communications. 358: 608-14. PMID 17502110 DOI: 10.1016/J.Bbrc.2007.04.177 |
0.313 |
|
| 2007 |
Muramatsu Y, Ohishi T, Sakamoto M, Tsuruo T, Seimiya H. Cross-species difference in telomeric function of tankyrase 1. Cancer Science. 98: 850-7. PMID 17433040 DOI: 10.1111/J.1349-7006.2007.00462.X |
0.376 |
|
| 2006 |
Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. British Journal of Cancer. 94: 341-5. PMID 16421589 DOI: 10.1038/Sj.Bjc.6602951 |
0.432 |
|
| 2006 |
Tahara H, Shin-Ya K, Seimiya H, Yamada H, Tsuruo T, Ide T. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene. 25: 1955-66. PMID 16302000 DOI: 10.1038/Sj.Onc.1209217 |
0.485 |
|
| 2006 |
Tahara H, Seimiya H, Shin-ya K, Ide T. 627 POSTER New screening technology for development of effective anti-cancer drugs targeting telomere G-tail Ejc Supplements. 4: 189. DOI: 10.1016/S1359-6349(06)70632-2 |
0.33 |
|
| 2005 |
Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell. 7: 25-37. PMID 15652747 DOI: 10.1016/J.Ccr.2004.11.021 |
0.419 |
|
| 2004 |
Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, Suster S, Morrison C, Jacob ST. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 101: 13844-9. PMID 15356345 DOI: 10.1073/Pnas.0405451101 |
0.372 |
|
| 2004 |
Seimiya H, Muramatsu Y, Smith S, Tsuruo T. Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl)ation of TRF1 and telomere elongation. Molecular and Cellular Biology. 24: 1944-55. PMID 14966275 DOI: 10.1128/Mcb.24.5.1944-1955.2004 |
0.451 |
|
| 2002 |
Seimiya H, Smith S. The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). The Journal of Biological Chemistry. 277: 14116-26. PMID 11854288 DOI: 10.1074/Jbc.M112266200 |
0.467 |
|
| 2001 |
Wang Z, Bhattacharya N, Meyer MK, Seimiya H, Tsuruo T, Tonani JA, Magnuson NS. Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Archives of Biochemistry and Biophysics. 390: 9-18. PMID 11368509 DOI: 10.1006/Abbi.2001.2370 |
0.327 |
|
| 2000 |
Seimiya H, Sawada H, Muramatsu Y, Shimizu M, Ohko K, Yamane K, Tsuruo T. Involvement of 14-3-3 proteins in nuclear localization of telomerase. The Embo Journal. 19: 2652-61. PMID 10835362 DOI: 10.1093/Emboj/19.11.2652 |
0.388 |
|
| 1999 |
Seimiya H, Tanji M, Oh-hara T, Tomida A, Naasani I, Tsuruo T. Hypoxia up-regulates telomerase activity via mitogen-activated protein kinase signaling in human solid tumor cells. Biochemical and Biophysical Research Communications. 260: 365-70. PMID 10403776 DOI: 10.1006/Bbrc.1999.0910 |
0.39 |
|
| 1999 |
Dan S, Naito M, Seimiya H, Kizaki A, Mashima T, Tsuruo T. Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. Oncogene. 18: 1277-83. PMID 10022809 DOI: 10.1038/Sj.Onc.1202423 |
0.325 |
|
| 1999 |
Chen Z, Seimiya H, Naito M, Mashima T, Kizaki A, Dan S, Imaizumi M, Ichijo H, Miyazono K, Tsuruo T. ASK1 mediates apoptotic cell death induced by genotoxic stress. Oncogene. 18: 173-80. PMID 9926932 DOI: 10.1038/Sj.Onc.1202276 |
0.301 |
|
| 1998 |
Mashima T, Seimiya H, Chen Z, Kataoka S, Tsuruo T. Apoptosis resistance in tumor cells. Cytotechnology. 27: 293-308. PMID 19002800 DOI: 10.1023/A:1008058031511 |
0.35 |
|
| 1998 |
Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochemical and Biophysical Research Communications. 249: 391-6. PMID 9712707 DOI: 10.1006/Bbrc.1998.9075 |
0.453 |
|
| 1998 |
Seimiya H, Tsuruo T. Functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of monoblastoid leukemia cells. The Journal of Biological Chemistry. 273: 21187-93. PMID 9694875 DOI: 10.1074/Jbc.273.33.21187 |
0.374 |
|
| 1998 |
Seimiya H, Tsuruo T. [Telomerase downregulation during differentiation of leukemia cells]. Nihon Rinsho. Japanese Journal of Clinical Medicine. 56: 1121-5. PMID 9613107 |
0.314 |
|
| 1998 |
Haga N, Naito M, Seimiya H, Tomida A, Dong J, Tsuruo T. 2-Deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukemia U937 cells with inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. International Journal of Cancer. Journal International Du Cancer. 76: 86-90. PMID 9533766 DOI: 10.1002/(Sici)1097-0215(19980330)76:1<86::Aid-Ijc14>3.0.Co;2-E |
0.356 |
|
| 1997 |
Seimiya H, Mashima T, Toho M, Tsuruo T. c-Jun NH2-terminal kinase-mediated activation of interleukin-1beta converting enzyme/CED-3-like protease during anticancer drug-induced apoptosis. The Journal of Biological Chemistry. 272: 4631-6. PMID 9020192 DOI: 10.1074/Jbc.272.7.4631 |
0.362 |
|
| 1995 |
Yamaki H, Nakajima M, Seimiya H, Saya H, Sugita M, Tsuruo T. Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase. The Journal of Antibiotics. 48: 1021-6. PMID 7592047 DOI: 10.7164/Antibiotics.48.1021 |
0.339 |
|
| 1993 |
Heike Y, Sone S, Yano S, Seimiya H, Tsuruo T, Ogura T. M-CSF gene transduction in multidrug-resistant human cancer cells to enhance anti-P-glycoprotein antibody-dependent macrophage-mediated cytotoxicity. International Journal of Cancer. Journal International Du Cancer. 54: 851-7. PMID 8100809 DOI: 10.1002/Ijc.2910540521 |
0.368 |
|
| 1993 |
Noguchi K, Naito M, Tezuka K, Ishii S, Seimiya H, Sugimoto Y, Amann E, Tsuruo T. cDNA expression cloning of the 85-kDa protein overexpressed in adriamycin-resistant cells. Biochemical and Biophysical Research Communications. 192: 88-95. PMID 7682812 DOI: 10.1006/Bbrc.1993.1385 |
0.336 |
|
| 1992 |
Ariyoshi K, Hamada H, Naito M, Heike Y, Seimiya H, Maezawa K, Tsuruo T. Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein. Japanese Journal of Cancer Research : Gann. 83: 515-21. PMID 1352281 DOI: 10.1111/J.1349-7006.1992.Tb01958.X |
0.308 |
|
| Show low-probability matches. |